Notable Labs

Notable Labs Gross Margin

The Gross Margin of Notable Labs (NTBLQ) as of Nov 10, 2026 is 36.45 %. In the previous year, Gross Margin was 83.33 % — a change of -56.26% (lower).

Gross Margin

36.45 %

YoY

-56.26%

Last updated:

Gross Margin of Notable Labs is 2023 36.45 % . Gross Margin of Notable Labs was 2022 83.33 % . It decreases by -56.26% lower compared to the previous year.

For Notable Labs, the gross margin of 36.5% is down versus 60.7% a few years ago.

The Notable Labs Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2017
97.55 USD
Jan 1, 2018
55.93 USD
Jan 1, 2019
60.71 USD
Jan 1, 2020
57.61 USD
Jan 1, 2021
51.95 USD
Jan 1, 2022
83.33 USD
Jan 1, 2023
36.45 USD
The Notable Labs Gross Margin history
YEARGross MarginYoY
36.45 %-56.26%
83.33 %+60.42%
51.95 %-9.83%
57.61 %-5.12%
60.71 %+8.55%
55.93 %-42.66%
97.55 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Notable Labs Stock analysis

What does Notable Labs do? Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company developing targeted medicines for cancer and immune-inflammatory diseases. The company leverages two platform technologies: Vascular Targeting System (VTS), a gene-based approach targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based method inhibiting monocyte migration. Its product candidates aim to improve patient outcomes by overcoming limitations of current treatments. The firm's pipeline focuses on difficult-to-treat conditions, with VTS and MTT serving as the core technologies for developing therapeutics. VTS targets cancer by focusing on blood vessel formation, while MTT addresses immune-inflammatory diseases through monocyte migration control. These technologies enable the creation of next-generation medicines that address unmet medical needs. Notable Labs Ltd sells its product candidates to pharmaceutical companies and healthcare providers for further development and clinical trials. The primary buyers are biopharmaceutical firms seeking innovative therapies, particularly those targeting cancer and immune-inflammatory conditions. The company's revenue model relies on licensing agreements and partnerships with these industry players to advance its pipeline. Notable Labs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Notable Labs stock

Gross Margin of Notable Labs is 36.45 % in 2023.

Gross Margin of Notable Labs changed from 83.33 % to 36.45 %, representing a -56.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Notable Labs since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Notable Labs with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Notable Labs

All Key Metrics — Notable Labs